δ-Opioid receptor agonists as a therapeutic approach in Parkinson's disease

Drug News and Perspectives

Volumn 13, Issue 5, 2000, Pages 261-268

  Hill, M P ^a   Hille, C J ^a   Brotchie, J M ^a  

^a Williams House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; OPIATE AGONIST; SIGMA OPIATE RECEPTOR;

DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG USE; HUMAN; PARKINSON DISEASE; REVIEW; TREATMENT INDICATION;

EID: 0033797368     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases
2. The pathology of the human locus ceruleus
3. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway
4. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis
5. Striatal dopamine deficiency in Parkinson's disease: Role of aging
6. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease
7. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA)
8. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications
9. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
10. Colloid (hyaline) inclusion bodies in the central nervous system: Their presence in the substantia nigra is diagnostic of Parkinson's disease
11. Pure akinesia due to Lewy body Parkinson's disease: A case with pathology
12. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism
13. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys
14. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
15. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus
16. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate
17. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats
18. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate
19. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys
20. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model
21. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat
22. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
23. Dopamine (3-hydroxy-tyramine) and brain function
24. Aromatic amino acids and modification of parkinsonism
25. Effects of the 1-amine-adamantanes at the MK-801 binding site of the NMDA receptor gated ion channel: A human postmortem study
26. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
27. Deprenyl in Parkinson's disease
28. The role of D-1 and D-2 receptors
29. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
30. COMT inhibition in the treatment of Parkinson's disease
31. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group
32. COMT inhibition: A new treatment strategy for Parkinson's disease
33. COMT inhibition with entacapone in the treatment of Parkinson's disease
34. COMT inhibitors in Parkinson's disease
35. Cholinergic-anticholinergic antagonism in parkinsonism
36. Pharmacologic treatment of parkinsonian tremor
37. On-off effects in patients with Parkinson's disease on chronic levodopa therapy
38. Treatment of Parkinson's disease
39. The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets
40. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset
41. Neurotensin in projection neurons of the striatum and nucleus accumbens, with reference to coexistence with enkephalin and GABA: An immunohistochemical study in the cat
42. On the role of GABA for striatal functions. Interaction between GABA and enkephalin in the pallidal systems
43. Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus
44. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
45. Novel approaches to the symptomatic treatment of parkinsonian syndromes: Alternatives and adjuncts to dopamine-replacement
46. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: Implications for the treatment of Parkinson's disease
47. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions
48. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys
49. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis
50. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
51. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
52. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
53. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients
54. Preprogenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease
55. Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors
56. Endogenous opioid peptides: Multiple agonists and receptors
57. Pharmacological characteristics of tremor; rigidity and hypokinesia induced by reserpine in rat
58. Does reserpine induce parkinsonian rigidity?
59. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats
60. Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice
61. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice
62. Postsynaptic dopamine/adenosine interaction: 1. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice
63. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist
64. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons
65. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
66. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
67. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
68. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations
69. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding
70. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys
71. Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism
72. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia